RxDoctor Payments Data

Brooke Houser

Optometrist · Fort Smith, ARNPI 1780188193

Payments from drug & device makers

$1,191in general payments, 2019–2025

Across 37 payments — averaging $32.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$338
  • Harrow Eye, LLC$317
  • Tarsus Pharmaceuticals, Inc.$115
  • Amgen$113
  • Oyster Point Pharma, Inc.$103
  • AbbVie$66
  • plus $139 from 5 others

What the payments were for

  • Food & beverage$1,191100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,191 in reported general payments places this provider in the 65th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$87,918
Medicare patients
454
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner38$75,293
RestasisCyclosporine55$45,731
VyzultaLatanoprostene Bunod24$7,690
CombiganBrimonidine Tartrate/Timolol16$3,406
Latanoprost311$2,856
Cyclosporine11$2,836
Timolol Maleate122$1,566
Prednisolone Acetate52$1,263
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$480
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha26$301
Brimonidine Tartrate35$202
ValacyclovirValacyclovir Hcl13$181
ErythromycinErythromycin Base15$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$115$75,29338 claims
AbbVieRestasis, Combigan$66$49,13771 claims
Bausch & Lomb Americas Inc.Vyzulta$338$7,69024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →